NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety and Immunogenicity of a Live Attenuated H7N9 Influenza Virus Vaccine in Healthy Adults

Phase 1

Completed

Conditions: Influenza A Virus, H7N9 Subtype

Interventions: Biological: Live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine
Biological: Inactivated subvirion H7N9 influenza vaccine

First Posted Date: 2013-11-26

Last Posted Date: 2016-07-27

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 48

Registration Number: NCT01995695

Locations: 🇺🇸
University of Rochester Medical Center, Rochester, New York, United States

Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01), Administered Intravenously or Subcutaneously to Healthy Adults

Phase 1

Completed

Conditions: HIV Infection
Monoclonal Antibody, Human
HIV Antibodies
Neutralizing Antibody
VRC01 Monoclonal Antibody

First Posted Date: 2013-11-25

Last Posted Date: 2019-12-17

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 29

Registration Number: NCT01993706

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Study of Safety and Immunogenicity of HIV Vaccines in Healthy Volunteers

Phase 1

Completed

Conditions: Vaccine Response

Interventions: Biological: Ad4-mgag
Biological: Ad4-EnvC150
Biological: gp 120 Protein Boost

First Posted Date: 2013-11-21

Last Posted Date: 2019-12-17

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 62

Registration Number: NCT01989533

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Study of Safety and Effectiveness of Intravenous Immunization With PfSPZ Vaccine in Healthy African Adults

Phase 1

Completed

Conditions: Malaria

Interventions: Biological: PfSPZ Vaccine
Drug: Placebo

First Posted Date: 2013-11-20

Last Posted Date: 2019-12-03

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 296

Registration Number: NCT01988636

Locations: 🇲🇱
University of Bamako, Bamako, Mali

Study of People With HIV Infection Who Have High Viral Loads Despite Combination Antiretroviral Therapy

Completed

Conditions: Acquired Immune Deficiency Syndrome Virus
AIDS Virus
Acquired Immunodeficiency Syndrome Virus
Human Immunodeficiency Virus
Human Immunodeficiency Viruses

First Posted Date: 2013-11-06

Last Posted Date: 2025-06-05

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 26

Registration Number: NCT01976715

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Safety, Tolerability, Drug Interactions, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive HIV-Infected Children Less Than 12 Years of Age

Phase 1

Withdrawn

Conditions: HIV Infections

Interventions: Drug: Rilpivirine

First Posted Date: 2013-11-03

Last Posted Date: 2021-11-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Registration Number: NCT01975012

A Retrospective Multicenter Study to Determine 5-Year Clinical Outcomes in Subjects Previously Enrolled in the CTOT-01 Study

Completed

Conditions: Kidney Disease
Kidney Failure
End Stage Renal Disease

First Posted Date: 2013-11-03

Last Posted Date: 2019-01-03

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 184

Registration Number: NCT01974999

Locations: 🇨🇦
University of Manitoba Health Sciences Centre, Winnipeg, Manitoba, Canada
🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States
🇺🇸
Emory University, Atlanta, Georgia, United States

and more 4 locations

Evaluation of Anti-Hemagglutinin (Anti-HA) Antibodies as Protection From the Flu in Healthy People

Phase 1

Completed

Conditions: Influenza

Interventions: Biological: Ca/04/2009/H1N1r Challenge Virus

First Posted Date: 2013-10-29

Last Posted Date: 2017-04-24

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 74

Registration Number: NCT01971255

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Evaluating the Safety and Immune Response to Three Different Prime-Boost HIV Vaccine Regimens in Healthy, HIV-Uninfected Adults

Phase 1

Withdrawn

Conditions: HIV Infections

Interventions: Biological: DNA CON-S env vaccine
Biological: DNA Mosaic env vaccine
Biological: Placebo
Biological: DNA Nat-B env vaccine
Biological: NYVAC CON-S env vaccine
Biological: NYVAC Nat-B env vaccine
Biological: NYVAC Mosaic env vaccine
Device: Biojector 2000® Needle-Free Injection Management System™ (Biojector 2000®)

First Posted Date: 2013-10-28

Last Posted Date: 2021-10-15

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Registration Number: NCT01970449

Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children

Phase 1

Completed

Conditions: Respiratory Syncytial Virus Infections

Interventions: Biological: RSV cps2 Vaccine
Biological: Placebo Vaccine

First Posted Date: 2013-10-23

Last Posted Date: 2021-07-26

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 51

Registration Number: NCT01968083

Locations: 🇺🇸
Rush Univ. Cook County Hosp. Chicago NICHD CRS, Chicago, Illinois, United States
🇺🇸
Miller Children's Hospital at Long Beach Memorial Medical Center, Long Beach, California, United States
🇺🇸
University of California, UC San Diego CRS, La Jolla, California, United States

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy